Toshifumi Yamaguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Toshifumi Yamaguchi has a total of 288 co-authors. Here are the top co-authors by number of shared publications:
- Katsunori Shinozaki
Division of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan
20 shared publications - Kensei Yamaguchi
Gastroenterological Chemotherapy Department, The Cancer Institute Hospital of JFCR, Tokyo, Japan
19 shared publications - Yukiya Narita
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan
19 shared publications - Akihito Tsuji
Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kita, Japan
18 shared publications - Hideaki Suna
Ono Pharmaceutical Co., Ltd., Osaka, Osaka, Japan
18 shared publications - Hiroki Hara
Department of Gastroenterology, Saitama Cancer Center, Saitama, Japan
18 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Elsevier in SSRN Electronic Journal
Impact of relative dose intensity of adjuvant fluoropyrimidine monotherapy on survival outcomes in patients with stage III colorectal cancer: A pooled analysis of four randomized phase III trials (JCOG2310AS5)
Background and Purpose: Adjuvant fluoropyrimidine (FP) as well as oxaliplatin is the key drug in stage III colorectal cancer (CRC). Reduced relative dose intensity (RDI) of oxaliplatin-based chemotherapy is associated with inferior survival, but the significance of RDI reduction during FP monotherapy is unknown.Materials and Methods: We pooled individual patient data from four JCOG randomized phase III trials of patients with pathological stage III CRC who received adjuvant FP monotherapy. RFS was the primary endpoint and OS the secondary endpoint, both measured from the end of adjuvant chemotherapy. RDI was the ratio of actual-to-planned dose. Candidate RDI cut-offs (50–90%, 5% increments) were explored separately in low-risk (pT1–3N1) and high-risk (pT4 and/or N2) groups using Cox regression models.Results: Among 2,892 patients (1,798 low-risk, 1,094 high-risk), 3-year RFS was 87.5% and 71.3%, respectively (HR 2.37; 95% CI [2.03–2.78]). In the high-risk group, RDI ≥70% was associated with better 3-year RFS than RDI <70% (72.9% vs 63.5%; HR 0.66[0.51–0.85]); no significant RFS cut-off emerged in the low-risk group. For OS, RDI ≥65% was associated with better 5-year OS than OS <65% in the high-risk group (85.6% vs 76.2%; HR 0.68; [0.49–0.94]) and the similar tendency was observed in the low risk group with a cutoff of 70% (95.6% vs 90.9%; HR 0.69 [0.47–0.99]).Conclusions: Reduced RDI of adjuvant FP monotherapy was associated with poorer RFS and OS, particularly in high-risk stage III CRC. These exploratory thresholds support maintaining adequate dose intensity, pending prospective validation.
- 7 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImpact of relative dose intensity of adjuvant fluoropyrimidine monotherapy on survival outcomes in patients with stage III colorectal cancer: A pooled analysis of four randomized phase III trials (JCOG2310AS5)
Background and Purpose: Adjuvant fluoropyrimidine (FP) as well as oxaliplatin is the key drug in stage III colorectal cancer (CRC). Reduced relative dose intensity (RDI) of oxaliplatin-based chemotherapy is associated with inferior survival, but the significance of RDI reduction during FP monotherapy is unknown.Materials and Methods: We pooled individual patient data from four JCOG randomized phase III trials of patients with pathological stage III CRC who received adjuvant FP monotherapy. RFS was the primary endpoint and OS the secondary endpoint, both measured from the end of adjuvant chemotherapy. RDI was the ratio of actual-to-planned dose. Candidate RDI cut-offs (50–90%, 5% increments) were explored separately in low-risk (pT1–3N1) and high-risk (pT4 and/or N2) groups using Cox regression models.Results: Among 2,892 patients (1,798 low-risk, 1,094 high-risk), 3-year RFS was 87.5% and 71.3%, respectively (HR 2.37; 95% CI [2.03–2.78]). In the high-risk group, RDI ≥70% was associated with better 3-year RFS than RDI <70% (72.9% vs 63.5%; HR 0.66[0.51–0.85]); no significant RFS cut-off emerged in the low-risk group. For OS, RDI ≥65% was associated with better 5-year OS than OS <65% in the high-risk group (85.6% vs 76.2%; HR 0.68; [0.49–0.94]) and the similar tendency was observed in the low risk group with a cutoff of 70% (95.6% vs 90.9%; HR 0.69 [0.47–0.99]).Conclusions: Reduced RDI of adjuvant FP monotherapy was associated with poorer RFS and OS, particularly in high-risk stage III CRC. These exploratory thresholds support maintaining adequate dose intensity, pending prospective validation.
- Open Access
- 16 September 2026
- Published by Springer Nature in Gastric Cancer
- Vol. 29 (6) , 1349-1359
A multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901)
Background: There is currently no established chemotherapy regimen for early recurrence of pathological stage III gastric cancer (GC) following adjuvant chemotherapy with docetaxel plus S-1 (DS) after D2 gastrectomy. We aimed to evaluate the efficacy and safety of ramucirumab plus irinotecan in patients with GC who experienced early recurrence during or within 6 months after DS adjuvant chemotherapy. Methods: This prospective, open-label, multicenter phase II trial enrolled eligible patients treated at 25 centers of the Osaka Gastrointestinal Cancer Chemotherapy Study Group in Japan. Patients received ramucirumab (8 mg/kg) and irinotecan (150 mg/m 2 ) every 2 weeks. The primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety. The sample size was set at 40 based on a threshold median OS of 7 months and an expected median OS of 11 months, with a one-sided alpha error of 0.05 and a power of 0.80. Results: Between November 2019 and July 2023, 43 patients were enrolled, and 39 were included in the analysis after excluding three ineligible patients and one who did not initiate protocol treatment. The median OS was 15.9 months (95% CI: 8.8–42.0; p = 0.003). The median PFS was 5.5 months (95% CI: 3.9–8.1), and the ORR was 38.5%. Grade ≥ 3 adverse events, including neutropenia (25.6%) and hypertension (25.6%), were observed in more than 20% of patients. Conclusion: Ramucirumab plus irinotecan demonstrated promising efficacy and manageable toxicity in patients with early recurrence of GC following adjuvant DS therapy. Trial registration: This study was prospectively registered in the Japan Registry of Clinical Trials (jRCTs05119071, October 6, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs051190071 ).
- 16 September 2026
- Published by Springer Nature in Gastric Cancer
- Vol. 29 (6) , 1349-1359
Open AccessA multicenter phase II trial of ramucirumab plus irinotecan for early recurrence of gastric cancer during or after adjuvant chemotherapy with docetaxel plus S-1 therapy: the RAMIEL trial (OGSG1901)
Background: There is currently no established chemotherapy regimen for early recurrence of pathological stage III gastric cancer (GC) following adjuvant chemotherapy with docetaxel plus S-1 (DS) after D2 gastrectomy. We aimed to evaluate the efficacy and safety of ramucirumab plus irinotecan in patients with GC who experienced early recurrence during or within 6 months after DS adjuvant chemotherapy. Methods: This prospective, open-label, multicenter phase II trial enrolled eligible patients treated at 25 centers of the Osaka Gastrointestinal Cancer Chemotherapy Study Group in Japan. Patients received ramucirumab (8 mg/kg) and irinotecan (150 mg/m 2 ) every 2 weeks. The primary endpoint was overall survival (OS), and secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and safety. The sample size was set at 40 based on a threshold median OS of 7 months and an expected median OS of 11 months, with a one-sided alpha error of 0.05 and a power of 0.80. Results: Between November 2019 and July 2023, 43 patients were enrolled, and 39 were included in the analysis after excluding three ineligible patients and one who did not initiate protocol treatment. The median OS was 15.9 months (95% CI: 8.8–42.0; p = 0.003). The median PFS was 5.5 months (95% CI: 3.9–8.1), and the ORR was 38.5%. Grade ≥ 3 adverse events, including neutropenia (25.6%) and hypertension (25.6%), were observed in more than 20% of patients. Conclusion: Ramucirumab plus irinotecan demonstrated promising efficacy and manageable toxicity in patients with early recurrence of GC following adjuvant DS therapy. Trial registration: This study was prospectively registered in the Japan Registry of Clinical Trials (jRCTs05119071, October 6, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs051190071 ).
- 16 July 2026
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
Three-Year Follow-Up of the Randomized Trial Comparing Open Versus Laparoscopic Surgery for Primary Tumor Resection in Patients With Non-Curable Stage IV Colon Cancer (JCOG1107)
BACKGROUND: JCOG1107 (UMIN-CTR, number UMIN000009715) was a non-inferiority phase III trial comparing laparoscopic and open surgery for symptomatic, non-curable stage IV colon cancer. The primary analysis confirmed the non-inferiority of laparoscopic surgery in terms of progression-free survival. OBJECTIVE: To compare long-term outcomes of laparoscopic and open surgery for stage IV colon cancer. DESIGN: Multicenter, open-label, randomized, controlled phase III trial. SETTING: Forty-two Japanese institutions. PATIENTS: Participants were considered eligible if they had pathologically confirmed adenocarcinoma or adenosquamous carcinoma with a primary tumor between the cecum and rectosigmoid, presenting with stenosis and/or bleeding, and one to three non-curable factors. The required sample size was 194 to ensure 70% power, a one-sided alpha of 5%, and a non-inferiority hazard ratio margin of 1.38. INTERVENTIONS: Patients were randomized to receive either open or laparoscopic primary tumor resection, followed by modified FOLFOX6 plus bevacizumab or capecitabine plus oxaliplatin with bevacizumab. MAIN OUTCOME MEASURES: The primary endpoint was progression-free survival. RESULTS: A total of 195 patients were randomized, including 95 open and 100 laparoscopic surgeries. Postoperative chemotherapy was given to 82 and 86 patients, respectively. The median follow-up period for all randomized patients was 24.4 months. Grade ≥3 late complications occurred in one open (1.1%) and two laparoscopic (2.0%) patients. Three-year progression-free survival was 5.3% (95% confidence interval: 2.0–11.0) for open surgery and 3.0% (0.8–7.8) for laparoscopic surgery (hazard ratio: 1.028; 95% confidence interval: 0.772–1.370; p for non-inferiority = 0.02). The three-year overall survival was 31.5% (22.5–41.0) and 28.5% (20.0–37.6) (hazard ratio: 1.048; 95% confidence interval: 0.780–1.410), respectively. LIMITATIONS: Chemotherapy was administered without knowledge of microsatellite instability or RAS/BRAF mutation status. CONCLUSION: Laparoscopic surgery is non-inferior to open surgery for non-curable stage IV colon cancer and should be considered an acceptable surgical option. See Video Abstract .
- 16 July 2026
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
Three-Year Follow-Up of the Randomized Trial Comparing Open Versus Laparoscopic Surgery for Primary Tumor Resection in Patients With Non-Curable Stage IV Colon Cancer (JCOG1107)
BACKGROUND: JCOG1107 (UMIN-CTR, number UMIN000009715) was a non-inferiority phase III trial comparing laparoscopic and open surgery for symptomatic, non-curable stage IV colon cancer. The primary analysis confirmed the non-inferiority of laparoscopic surgery in terms of progression-free survival. OBJECTIVE: To compare long-term outcomes of laparoscopic and open surgery for stage IV colon cancer. DESIGN: Multicenter, open-label, randomized, controlled phase III trial. SETTING: Forty-two Japanese institutions. PATIENTS: Participants were considered eligible if they had pathologically confirmed adenocarcinoma or adenosquamous carcinoma with a primary tumor between the cecum and rectosigmoid, presenting with stenosis and/or bleeding, and one to three non-curable factors. The required sample size was 194 to ensure 70% power, a one-sided alpha of 5%, and a non-inferiority hazard ratio margin of 1.38. INTERVENTIONS: Patients were randomized to receive either open or laparoscopic primary tumor resection, followed by modified FOLFOX6 plus bevacizumab or capecitabine plus oxaliplatin with bevacizumab. MAIN OUTCOME MEASURES: The primary endpoint was progression-free survival. RESULTS: A total of 195 patients were randomized, including 95 open and 100 laparoscopic surgeries. Postoperative chemotherapy was given to 82 and 86 patients, respectively. The median follow-up period for all randomized patients was 24.4 months. Grade ≥3 late complications occurred in one open (1.1%) and two laparoscopic (2.0%) patients. Three-year progression-free survival was 5.3% (95% confidence interval: 2.0–11.0) for open surgery and 3.0% (0.8–7.8) for laparoscopic surgery (hazard ratio: 1.028; 95% confidence interval: 0.772–1.370; p for non-inferiority = 0.02). The three-year overall survival was 31.5% (22.5–41.0) and 28.5% (20.0–37.6) (hazard ratio: 1.048; 95% confidence interval: 0.780–1.410), respectively. LIMITATIONS: Chemotherapy was administered without knowledge of microsatellite instability or RAS/BRAF mutation status. CONCLUSION: Laparoscopic surgery is non-inferior to open surgery for non-curable stage IV colon cancer and should be considered an acceptable surgical option. See Video Abstract .
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2500941
Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study
PURPOSE: The Shield test is a blood-based assay that uses multimodal analysis of cell-free DNA (cfDNA) to enable noninvasive colorectal cancer (CRC) detection. The aim of this study was to assess the diagnostic performance of the cfDNA test for CRC and advanced precancerous lesions (APLs) and evaluate its potential clinical utility, particularly in early-stage disease. METHODS: In this prospective, multicenter study, 451 patients with histologically confirmed CRC or APLs were enrolled across eight institutions. Blood samples collected before treatment were analyzed using the cfDNA test (Shield, Guardant Health, United States). We assessed the sensitivity of the test for different CRC stages and APLs. In addition, we examined the correlation between test positivity and clinicopathologic factors in stage I and T1 CRC. RESULTS: The test showed 87.9% sensitivity for CRC overall, with stage-specific sensitivities of 71.2% for stage I and 97.4% for stages II-IV. Sensitivity for APLs was 37.0%. In stage I CRC, test positivity was significantly associated with tumor depth (T2: 88.6% v T1: 59.7%, P < .01). Among 70 patients with T1 CRC, the test detected all to have lymph node metastasis (LNM; 100% sensitivity). Compared with guideline-based pathologic criteria, the cfDNA test achieved higher specificity for LNM prediction (38.7% v 11.3%), thereby potentially reducing the frequency of unnecessary radical surgery from 78.6% to 54.3%. CONCLUSION: This cfDNA blood-based test shows a robust diagnostic performance in CRC detection. It may improve risk stratification and support more tailored clinical decision making, particularly in the management of T1 CRC.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 10 (7) , e2500941
Open AccessCell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study
PURPOSE: The Shield test is a blood-based assay that uses multimodal analysis of cell-free DNA (cfDNA) to enable noninvasive colorectal cancer (CRC) detection. The aim of this study was to assess the diagnostic performance of the cfDNA test for CRC and advanced precancerous lesions (APLs) and evaluate its potential clinical utility, particularly in early-stage disease. METHODS: In this prospective, multicenter study, 451 patients with histologically confirmed CRC or APLs were enrolled across eight institutions. Blood samples collected before treatment were analyzed using the cfDNA test (Shield, Guardant Health, United States). We assessed the sensitivity of the test for different CRC stages and APLs. In addition, we examined the correlation between test positivity and clinicopathologic factors in stage I and T1 CRC. RESULTS: The test showed 87.9% sensitivity for CRC overall, with stage-specific sensitivities of 71.2% for stage I and 97.4% for stages II-IV. Sensitivity for APLs was 37.0%. In stage I CRC, test positivity was significantly associated with tumor depth (T2: 88.6% v T1: 59.7%, P < .01). Among 70 patients with T1 CRC, the test detected all to have lymph node metastasis (LNM; 100% sensitivity). Compared with guideline-based pathologic criteria, the cfDNA test achieved higher specificity for LNM prediction (38.7% v 11.3%), thereby potentially reducing the frequency of unnecessary radical surgery from 78.6% to 54.3%. CONCLUSION: This cfDNA blood-based test shows a robust diagnostic performance in CRC detection. It may improve risk stratification and support more tailored clinical decision making, particularly in the management of T1 CRC.
- Open Access
- 15 March 2026
- Published by Springer Nature in Targeted Oncology
- Vol. 21 (2) , 269-283
Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer
Background While oncogene co-amplification is frequently observed, its clinical significance remains unclear, particularly with regard to its association with copy number. Objective The aim of this study was to elucidate the molecular traits of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, focusing on copy numbers of ERBB2 and other oncogenes, and to investigate their association with treatment efficacy. Methods This is a collaborative study associated with the HIGHSOX trial investigating the efficacy of trastuzumab combined with S-1 and oxaliplatin in HER2-positive gastric cancer, and next-generation sequencing was performed. Tumors in which ERBB2 was the highest copy number among co-amplified oncogenes were defined as “ERBB2 dominant”. The others were defined as “non-ERBB2 dominant”. Results A total of 32 patients were enrolled, and the median progression-free survival and overall survival were 11.8 and 28.8 months, respectively. ERBB2 amplification was present in 84.4%, with the majority (88%) exhibiting either co-amplification of ERBB2 with other oncogenes (75%) or amplification of other oncogenes alone (13%), including KRAS, MET, FGFR2, and CCNE1. A potential inverse relationship in copy number between ERBB2 and other oncogenes (ρ = − 0.345, p = 0.058) was observed. The ERBB2 copy number was significantly higher than that of other oncogenes in ERBB2-dominant tumors, whereas the opposite pattern was observed in non-ERBB2-dominant tumors (both p < 0.001). Non-ERBB2-dominant tumors showed significantly shorter progression-free survival (median progression-free survival: 6.9 vs 17.0 months, hazard ratio, 6.40, p = 0.001), overall survival (median overall survival 14.8 vs 35.5 months, hazard ratio, 2.72, p = 0.016), and a numerically lower response rate (63.6% vs 90.0%, p = 0.151). Conclusions Copy number-based oncogene dominance may suggest tumor dependence and response to HER2-targeted therapy, highlighting a potential novel biomarker in HER2-positive gastric cancer.
- 15 March 2026
- Published by Springer Nature in Targeted Oncology
- Vol. 21 (2) , 269-283
Open AccessCopy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer
Background While oncogene co-amplification is frequently observed, its clinical significance remains unclear, particularly with regard to its association with copy number. Objective The aim of this study was to elucidate the molecular traits of human epidermal growth factor receptor 2 (HER2)-positive gastric cancer, focusing on copy numbers of ERBB2 and other oncogenes, and to investigate their association with treatment efficacy. Methods This is a collaborative study associated with the HIGHSOX trial investigating the efficacy of trastuzumab combined with S-1 and oxaliplatin in HER2-positive gastric cancer, and next-generation sequencing was performed. Tumors in which ERBB2 was the highest copy number among co-amplified oncogenes were defined as “ERBB2 dominant”. The others were defined as “non-ERBB2 dominant”. Results A total of 32 patients were enrolled, and the median progression-free survival and overall survival were 11.8 and 28.8 months, respectively. ERBB2 amplification was present in 84.4%, with the majority (88%) exhibiting either co-amplification of ERBB2 with other oncogenes (75%) or amplification of other oncogenes alone (13%), including KRAS, MET, FGFR2, and CCNE1. A potential inverse relationship in copy number between ERBB2 and other oncogenes (ρ = − 0.345, p = 0.058) was observed. The ERBB2 copy number was significantly higher than that of other oncogenes in ERBB2-dominant tumors, whereas the opposite pattern was observed in non-ERBB2-dominant tumors (both p < 0.001). Non-ERBB2-dominant tumors showed significantly shorter progression-free survival (median progression-free survival: 6.9 vs 17.0 months, hazard ratio, 6.40, p = 0.001), overall survival (median overall survival 14.8 vs 35.5 months, hazard ratio, 2.72, p = 0.016), and a numerically lower response rate (63.6% vs 90.0%, p = 0.151). Conclusions Copy number-based oncogene dominance may suggest tumor dependence and response to HER2-targeted therapy, highlighting a potential novel biomarker in HER2-positive gastric cancer.
- Open Access
- 26 February 2026
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 17 (3) , 604-613
Impact of Skeletal Muscle-related Parameters on Survival in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine plus Nab-paclitaxel as First-line Chemotherapy
Background: Sarcopenia, defined as a reduction in muscle mass assessed using scales such as the psoas muscle mass index (PMI), is accompanied by decreased muscle strength or physical function. However, sarcopenia's effect in patients with pancreatic cancer (PC) receiving chemotherapy remains unclear. In addition, recent international studies have demonstrated that intramuscular fat infiltration, assessed using parameters such as FRPM, is associated with poor prognosis across various malignancies. However, evidence regarding its prognostic significance in pancreatic cancer remains limited. We aimed to evaluate the relationship between sarcopenia and the prognosis of patients with PC receiving palliative chemotherapy.
- 26 February 2026
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 17 (3) , 604-613
Open AccessImpact of Skeletal Muscle-related Parameters on Survival in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine plus Nab-paclitaxel as First-line Chemotherapy
Background: Sarcopenia, defined as a reduction in muscle mass assessed using scales such as the psoas muscle mass index (PMI), is accompanied by decreased muscle strength or physical function. However, sarcopenia's effect in patients with pancreatic cancer (PC) receiving chemotherapy remains unclear. In addition, recent international studies have demonstrated that intramuscular fat infiltration, assessed using parameters such as FRPM, is associated with poor prognosis across various malignancies. However, evidence regarding its prognostic significance in pancreatic cancer remains limited. We aimed to evaluate the relationship between sarcopenia and the prognosis of patients with PC receiving palliative chemotherapy.
- Open Access
- 21 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 2651
Correction: The efficacy of adjuvant chemotherapy after total mesorectal excision without selective lateral lymph node dissection for locally advanced rectal cancer
- 21 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 2651
Open AccessCorrection: The efficacy of adjuvant chemotherapy after total mesorectal excision without selective lateral lymph node dissection for locally advanced rectal cancer
- 21 January 2026
- Published by Springer Nature in Gastric Cancer
- Vol. 29 (2) , 387-397
Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902)
Background Large type 3 (≥ 8 cm) and type 4 gastric cancers are associated with extremely poor prognoses. The phase III JCOG0501 trial, which evaluated neoadjuvant S-1 plus cisplatin, failed to demonstrate any survival benefits. Docetaxel, oxaliplatin, and S-1 (DOS) have been explored as more effective perioperative regimens for these tumors. Methods Eligible patients had large type 3 or type 4 gastric cancer without distant metastases, except for positive peritoneal cytology (CY). Patients received three cycles of neoadjuvant DOS (docetaxel 40 mg/m2, oxaliplatin 100 mg/m2, and oral S-1 at 80 mg/m2/day for 14 days), followed by gastrectomy with ≥ D2 lymphadenectomy and one year of adjuvant docetaxel plus S-1. The primary endpoint was the 3 year progression-free survival (PFS) rate, with an expected value of 60% and a threshold of 45%. A one-sample log-rank test was performed with an α level of 0.10. Results Of the 48 patients enrolled, 27 had type 4 tumors (56.2%), and 10 (20.8%) had CY1. Overall, 91.7% of patients completed neoadjuvant DOS. R0 resection rate was achieved in 89.6% of patients, a pathological response grade ≥ 1b in 66.7%, and negative CY conversion in 80.0%. The 3-year PFS rate was 37.5% (95% confidence interval [CI], 24.1–50.6%; 80% CI 28.6–46.4%; p = 0.960), and the 3-year overall survival rate was 52.1% (95% CI 37.2–65.0%). Conclusions Although neoadjuvant DOS therapy demonstrated favorable pathological responses, the 3-year PFS did not exceed the predefined threshold, and a survival benefit was not demonstrated.
- 21 January 2026
- Published by Springer Nature in Gastric Cancer
- Vol. 29 (2) , 387-397
Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902)
Background Large type 3 (≥ 8 cm) and type 4 gastric cancers are associated with extremely poor prognoses. The phase III JCOG0501 trial, which evaluated neoadjuvant S-1 plus cisplatin, failed to demonstrate any survival benefits. Docetaxel, oxaliplatin, and S-1 (DOS) have been explored as more effective perioperative regimens for these tumors. Methods Eligible patients had large type 3 or type 4 gastric cancer without distant metastases, except for positive peritoneal cytology (CY). Patients received three cycles of neoadjuvant DOS (docetaxel 40 mg/m2, oxaliplatin 100 mg/m2, and oral S-1 at 80 mg/m2/day for 14 days), followed by gastrectomy with ≥ D2 lymphadenectomy and one year of adjuvant docetaxel plus S-1. The primary endpoint was the 3 year progression-free survival (PFS) rate, with an expected value of 60% and a threshold of 45%. A one-sample log-rank test was performed with an α level of 0.10. Results Of the 48 patients enrolled, 27 had type 4 tumors (56.2%), and 10 (20.8%) had CY1. Overall, 91.7% of patients completed neoadjuvant DOS. R0 resection rate was achieved in 89.6% of patients, a pathological response grade ≥ 1b in 66.7%, and negative CY conversion in 80.0%. The 3-year PFS rate was 37.5% (95% confidence interval [CI], 24.1–50.6%; 80% CI 28.6–46.4%; p = 0.960), and the 3-year overall survival rate was 52.1% (95% CI 37.2–65.0%). Conclusions Although neoadjuvant DOS therapy demonstrated favorable pathological responses, the 3-year PFS did not exceed the predefined threshold, and a survival benefit was not demonstrated.
- Open Access
- 18 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 44088
The efficacy of adjuvant chemotherapy after total mesorectal excision without selective lateral lymph node dissection for locally advanced rectal cancer
The standard treatment for locally advanced rectal cancer (RC) in Japan is TME with or without lateral lymph node dissection (LLND) and subsequent adjuvant chemotherapy. The efficacy of chemotherapy after TME without LLND remains unclear, so we aimed to assess this efficacy. We retrospectively reviewed patients who underwent TME without LLND and received adjuvant chemotherapy between January 2010 and December 2020 at our institution. Relapse-free survival (RFS) and overall survival (OS) were assessed. Prognostic factors for RFS, including tumor location, chemotherapy regimen, and T and N factors were analyzed using univariate and multivariate analyses. Of 197 patients, 117 were eligible. The median age was 66 years (range 26–82). Tumor locations were Ra and Rb in 67 (57%) and 50 (43%) patients. Eighty (68%) and 37 (32%) patients received fluoropyrimidine monotherapy (single agent) and oxaliplatin-based therapy (doublet) as adjuvant chemotherapy. The 3-year RFS rate and 3-year OS rate were 73.6% (95% confidence interval [CI], 64.7–81.0%) and 95.5% (95% CI, 89.6–98.1%), respectively. In the univariate and multivariate analysis, none of these variables were identified as independent prognostic factors for RFS. TME without LLND followed by adjuvant chemotherapy in patients with RC demonstrated favorable 3-year RFS and OS rates.
- 18 December 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 44088
Open AccessThe efficacy of adjuvant chemotherapy after total mesorectal excision without selective lateral lymph node dissection for locally advanced rectal cancer
The standard treatment for locally advanced rectal cancer (RC) in Japan is TME with or without lateral lymph node dissection (LLND) and subsequent adjuvant chemotherapy. The efficacy of chemotherapy after TME without LLND remains unclear, so we aimed to assess this efficacy. We retrospectively reviewed patients who underwent TME without LLND and received adjuvant chemotherapy between January 2010 and December 2020 at our institution. Relapse-free survival (RFS) and overall survival (OS) were assessed. Prognostic factors for RFS, including tumor location, chemotherapy regimen, and T and N factors were analyzed using univariate and multivariate analyses. Of 197 patients, 117 were eligible. The median age was 66 years (range 26–82). Tumor locations were Ra and Rb in 67 (57%) and 50 (43%) patients. Eighty (68%) and 37 (32%) patients received fluoropyrimidine monotherapy (single agent) and oxaliplatin-based therapy (doublet) as adjuvant chemotherapy. The 3-year RFS rate and 3-year OS rate were 73.6% (95% confidence interval [CI], 64.7–81.0%) and 95.5% (95% CI, 89.6–98.1%), respectively. In the univariate and multivariate analysis, none of these variables were identified as independent prognostic factors for RFS. TME without LLND followed by adjuvant chemotherapy in patients with RC demonstrated favorable 3-year RFS and OS rates.
- Open Access
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Post-progression anti-cancer therapy of the nivolumab monotherapy
- 15 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Post-progression anti-cancer therapy of the nivolumab monotherapy